{"id":6659,"date":"2024-11-21T14:49:50","date_gmt":"2024-11-21T13:49:50","guid":{"rendered":"https:\/\/beigen.vipdev.lndo.site\/us\/?post_type=publication&p=6659"},"modified":"2025-04-28T21:49:00","modified_gmt":"2025-04-28T19:49:00","slug":"tislelizumab-in-previously-treated-locally-advanced-unresectable-metastatic-microsatellite-instability-high-mismatch-repair-deficient-solid-tumors","status":"publish","type":"publication","link":"https:\/\/beonemedaffairs.com\/us\/publication\/tislelizumab-in-previously-treated-locally-advanced-unresectable-metastatic-microsatellite-instability-high-mismatch-repair-deficient-solid-tumors\/","title":{"rendered":"Tislelizumab in previously treated, locally advanced unresectable\/metastatic microsatellite instability-high\/mismatch repair-deficient solid tumors\u00a0"},"content":{"rendered":"","protected":false},"template":"","post-tag":[],"class_list":["post-6659","publication","type-publication","status-publish","hentry","disease_state-colorectal-cancer","disease_state-gastic-gastroesophageal-junction-cancer","disease_state-ovarian-cancer","molecule-tislelizumab"],"acf":[],"_links":{"self":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/publication\/6659","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/publication"}],"about":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/types\/publication"}],"wp:attachment":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/media?parent=6659"}],"wp:term":[{"taxonomy":"post-tag","embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag?post=6659"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}